BEAM 302
Alternative Names: BEAM-302Latest Information Update: 12 Jul 2024
Price :
$50 *
At a glance
- Originator Beam Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Alpha 1-antitrypsin deficiency
Most Recent Events
- 19 Jun 2024 Phase-I/II clinical trials in Alpha 1-antitrypsin deficiency in United Kingdom (Parenteral) (NCT06389877)
- 07 Sep 2023 Beam Therapeutics plans to submit a regulatory application for authorization to initiate clinical trials for Alpha-1 antitrypsin deficiency in 1Q 2024
- 07 Sep 2023 Pharmacodynamics data from pre-clinical trial in Alpha 1-antitrypsin deficiency released by Beam Therapeutics